Endocardial Solutions Announces First Quarter 2000 Results

April 13, 2000

MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) today announced results for the first quarter ended March 31, 2000.

Revenues for the three-month period were $3,360,059, compared to revenues of $1,293,381 for the same period of 1999. The net loss for the three months ended March 31, 2000, is $2,502,415, or $.25 per share, compared to a net loss of $2,913,082, or $.32 per share, for the same period of 1999.

<*dv_1*>"The results for the first quarter demonstrate consistent progress in market penetration of the EnSite 3000® System. Our most important indicator of clinical acceptance this quarter is improved catheter utilization in trained accounts," said Jim Bullock, president and chief executive officer. "While the capital equipment market within U.S. hospitals remains challenging, we have implemented a number of programs to minimize this capital barrier."

<*dv_2*>"We have some very exciting near term events. We have more than 16 scientific presentations at the North American Society of Pacing and Electrophysiology (NASPE) in May and our second annual Complex Arrhythmias Mapping Symposium (CAMS) will take place in June. In addition, Clarity, our next generation software, will be submitted to the FDA in early May. This software will greatly simplify the user interface, thereby reducing the time it takes to train hospital staff," said Bullock.

The company began recording revenue from U.S. sales in the second quarter 1999. Gross margin for the quarter ended March 31, 2000, was 44.2%, compared to a negative 11.5% for the quarter ended March 31, 1999. Operating expenses increased $1,130,650 to $3,949,721 for the quarter ended March 31, 2000, because of the establishment of a U.S. sales and clinical team.

The U.S. Food and Drug Administration cleared the EnSite 3000® System for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart during the second quarter 1999. Through a distribution agreement with Medtronic, Inc., the EnSite 3000® System and catheter have been available to electrophysiologists in Europe since the second quarter 1998.

Based in St. Paul, Minnesota, Endocardial Solutions develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart). The EnSite 3000® System provides a 3D graphical display of the heart's electrical activity.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions' Form 10-K for the quarter ended December 31, 1999, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions.